Publications by authors named "P Dogterom"

Claim this Profile
N
New insights into the effects of dissolution profiles on the pharmacokinetics of trientine dihydrochloride.
Karl Heinz Weiss, Carlot Kruse, Khalid Abd-Elaziz, Eric van der Horst, ChauHwei Fu, Peter Dogterom

Eur J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
Vassilios Aslanis, Khalid Abd-Elaziz, Robert J Slack, Anne Brinch, Lise Gravelle, Peter Dogterom

Cancer Chemother Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5.
Nicholas P France, Christopher Rubino, M Courtney Safir, Mari Maurer, Tram Duong, Peter Dogterom

Clin Pharmacol Drug Dev· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study.
Valérie Bourdès, Peter Dogterom, André Aleman, Pierre Parmantier, Damien Colas

Neurol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects.
Karl Heinz Weiss, Catherine Thompson, Peter Dogterom, Yi-Jin Chiou, Tim Morley

Eur J Drug Metab Pharmacokinet· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis